The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort) easlfibronostg on June 29, 2026 Category: Publications Tag: Clinical Pathway, LIVERFASt, MASH, Monitoring, Resmetirom Post navigation Previous: Previous post: Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)Next: Next post: Correlations between LIVERFASt, MRE for fibrosis assessment and ICFF for steatosis assessment in MASLD patients
